The purpose of this study is to examine the efficacy of three doses of prednisone, a glucocorticoid, in treatment of patients with symptomatic heart failure.
Heart failure is a leading cause of cardiovascular morbidity and mortality in the world. Most patients with acute symptomatic heart failure are admitted with fluid overload. Intravenous loop diuretics are an essential component of current treatment in such patients. Newly emerging evidence showed that glucocorticoids could potentiate natriuretic peptides' action by upregulating the expression natriuretic peptide receptor A (NPR-A) in the kidney, and produce a potent diuresis. Therefore, the investigators designed this nonblinded, randomized dose comparison study to compare the efficacy of prednisone at 15, 30 and 60 mg/day in patients with in symptomatic heart failure.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
40
The patients with symptomatic heart failure are treated with prednisone at dose of 15 mg/day.
The patients with symptomatic heart failure are treated with prednisone at dose of 30 mg/day
The patients with symptomatic heart failure are treated with prednisone at dose of 60 mg/day
The First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
The First Hospital of Hebei Medical University
Shijiazhuang, China
Daily urinary volumes
Daily urinary volumes will be monitored for 10 days.
Time frame: 10 days
Urinary sodium excretion
Daily sodium exretions will be assessed at baseline, day 5 and day 10.
Time frame: 10 days
The effect of prednisone on renin angiotensin aldosterone system.
The effect of prednisone on patients' renin angiotensin aldosterone system, such as renin activity, plasma Ang I, plasma Ang II, and plasma aldosterone will be will be assessed on baseline, day 5 and day 10.
Time frame: 10 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.